The clinical course of 239 cases of Japanese spotted fever in Ise Red Cross Hospital, 2006–2019
- 25 October 2021
- journal article
- research article
- Published by Elsevier BV in Journal of Infection and Chemotherapy
- Vol. 28 (2), 211-216
- https://doi.org/10.1016/j.jiac.2021.10.014
Abstract
No abstract availableThis publication has 23 references indexed in Scilit:
- Analysis of risk factors for malignant Mediterranean spotted fever indicates that fluoroquinolone treatment has a deleterious effectJournal of Antimicrobial Chemotherapy, 2011
- Prevalence of Bacterial Agents in Ixodes persulcatus Ticks from the Vologda Province of RussiaAnnals of the New York Academy of Sciences, 2006
- Japanese Spotted Fever, South KoreaEmerging Infectious Diseases, 2006
- Mediterranean Spotted Fever in PortugalAnnals of the New York Academy of Sciences, 2003
- Analysis of Risk Factors for Fatal Rocky Mountain Spotted Fever: Evidence for Superiority of Tetracyclines for TherapyThe Journal of Infectious Diseases, 2001
- Tetracycline Antibiotics: Mode of Action, Applications, Molecular Biology, and Epidemiology of Bacterial ResistanceMicrobiology and Molecular Biology Reviews, 2001
- Fulminant Japanese Spotted Fever Associated with HypercytokinemiaJournal of Clinical Microbiology, 2001
- Japanese Spotted Fever: Report of 31 Cases and Review of the LiteratureEmerging Infectious Diseases, 1997
- Therapeutic Delay and Mortality in Cases of Rocky Mountain Spotted FeverClinical Infectious Diseases, 1995
- Randomized double-blind evaluation of ciprofloxacin and doxycycline for Mediterranean spotted feverAntimicrobial Agents and Chemotherapy, 1989